In a mouse model of anti-tumor immunity, the TLR9 agonist CpG has been shown to enhance the CD8 T cell response in vitro, in a B cell and contact-dependent manner, resulting in an improved tumor growth control and a higher mouse survival (52). Here, CD8A is linked to neoplasm.